Highlights SELLAS Life Sciences Group, Inc.

Equities

SLS

US81642T2096

Market Closed - Nasdaq Other stock markets 16:00:00 2024-05-14 EDT			Pre-market 07:05:02
1.37 ^USD	0.00%		1.37	0.00%

05-01	SELLAS Life Sciences Group, Inc. Announces Positive Phase 2 Preliminary Data of SLS009 in r/r AML Achieving a 100% Response Rate in Patients with ASXL1 Mutation At the Optimal Dose Level	CI
04-29	SELLAS Life Sciences Group, Inc. Announces Positive Recommendation of Independent Data Monitoring Committee Following Completion of Enrollment in REGAL Phase 3 Study	CI

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

SELLAS Life Sciences Group, Inc. Announces Positive Phase 2 Preliminary Data of SLS009 in r/r AML Achieving a 100% Response Rate in Patients with ASXL1 Mutation At the Optimal Dose Level	05-01	CI
SELLAS Life Sciences Group, Inc. Announces Positive Recommendation of Independent Data Monitoring Committee Following Completion of Enrollment in REGAL Phase 3 Study	04-29	CI
SELLAS Life Sciences Group, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	03-28	CI
SELLAS Life Sciences Group, Inc. Announces Positive Topline Data from the Phase 2a Study of Sls009 in r/r AML	03-26	CI
SELLAS Life Sciences Group, Inc. Receives FDA Fast Track Designation for SLS009 for Treatment of Relapsed/Refractory Acute Myeloid Leukemia and Provides Updated Data for Phase 2a Study of SLS009 in Relapsed/Refractory Acute Myeloid Leukemia Patients	01-09	CI
Exchange-Traded Funds, Equity Futures Mixed Pre-Bell Thursday as Traders Mull Fed Meeting Minutes	01-04	MT
SELLAS Life Sciences Group, Inc. Reports Positive Follow-Up Immune Response and Survival Data in Completed Phase 1 Study of Galinpepimut-S Combined with Opdivo® in Advanced Malignant Pleural Mesothelioma	12-27	CI
SELLAS Life Sciences Seeks Arbitration in Dispute with 3D Medicines	12-27	MT
Sellas Life Sciences Announces First Patients Enrolled in 60 Mg Dose Cohort in Phase 2A Clinical Trial of Sls009 in Acute Myeloid Leukemia	12-14	CI
Sellas Life Sciences Announces Positive Recommendation from Regal Independent Data Monitoring Committee of Galinpepimut-S in Acute Myeloid Leukemia	12-04	CI
SELLAS Life Sciences Group, Inc. Reaches Target Enrollment Ex-China in Phase 3 Regal Trial of Galinpepimut-S in Acute Myeloid Leukemia	11-29	CI
SELLAS Life Sciences Group, Inc. Receives Favorable FDA Type C Meeting Feedback on Chemistry, Manufacturing, and Controls Biologics License Application Filing Strategy for Galinpepimut-S	11-13	CI
SELLAS Life Sciences Group, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	11-09	CI
SELLAS Life Sciences Group, Inc. Presents Positive Key Immunobiological and Clinical Data from Phase 1/2 Trial of galinpepimut-S in Combination with Keytruda in WT1+ Platinum-Resistant Advanced Ovarian Cancer at International Gynecologic Cancer Society 2023 Annual Global Meeting	11-06	CI
SELLAS Gets FDA's Fast-Track Label for Treatment of Peripheral T-Cell Lymphomas	23-10-30	MT
SELLAS Life Sciences Group, Inc. Announces Positive Initial Topline Phase 2a Data of SLS009 in Acute Myeloid Leukemia	23-10-16	CI
SELLAS Life Sciences Group, Inc. Provides Update on Phase 3 Regal Clinical Trial for Galinpepimut-S in Acute Myeloid Leukemia	23-10-13	CI
SELLAS Announces First Patient Dosed in Phase Ib/II Trial of SLS009 in Relapsed/Refractory Peripheral T-cell Lymphomas	23-10-11	CI
SELLAS Life Sciences Gets FDA Orphan Drug Designation for Acute Myeloid Leukemia Treatment; Shares Jump After Hours	23-10-10	MT
Sellas Life Sciences Group Gets FDA Orphan Drug Designation to Treat Type of Leukemia	23-10-10	DJ

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights SELLAS Life Sciences Group, Inc.

Equities

SLS

US81642T2096

Highlights

Filters